EyePoint Pharmaceuticals, Inc.EYPTNASDAQ
Loading
Year-over-year operating cash flow growth rate
Percentile
P46
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -9.59% |
| Q3 2025 | 5.17% |
| Q2 2025 | -17.83% |
| Q1 2025 | -48.18% |
| Q4 2024 | 8.15% |
| Q3 2024 | -93.42% |
| Q2 2024 | 35.27% |
| Q1 2024 | -34.89% |
| Q4 2023 | -51.99% |
| Q3 2023 | -126.66% |
| Q2 2023 | 438.72% |
| Q1 2023 | -33.74% |
| Q4 2022 | 4.17% |
| Q3 2022 | 31.31% |
| Q2 2022 | 5.13% |
| Q1 2022 | -20.94% |
| Q4 2021 | -114.05% |
| Q3 2021 | 26.14% |
| Q2 2021 | 30.17% |
| Q1 2021 | -356.13% |
| Q4 2020 | 418.93% |
| Q3 2020 | 122.18% |
| Q2 2020 | 68.67% |
| Q1 2020 | -42.30% |
| Q4 2019 | 22.24% |
| Q3 2019 | 13.65% |
| Q2 2019 | -28.30% |
| Q1 2019 | -23.23% |
| Q4 2018 | 8.04% |
| Q3 2018 | -93.49% |
| Q2 2018 | -26.16% |
| Q1 2018 | 4.33% |
| Q4 2017 | 15.58% |
| Q3 2017 | -34.05% |
| Q2 2017 | 2.00% |
| Q1 2017 | 9.30% |
| Q4 2016 | 22.77% |
| Q3 2016 | -49.21% |
| Q2 2016 | -1.05% |
| Q1 2016 | -35.54% |